A detailed history of China Universal Asset Management Co., Ltd. transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 8,100 shares of URGN stock, worth $86,184. This represents 0.01% of its overall portfolio holdings.

Number of Shares
8,100
Previous 4,244 90.86%
Holding current value
$86,184
Previous $71,000 43.66%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$12.7 - $17.92 $48,971 - $69,099
3,856 Added 90.86%
8,100 $102,000
Q2 2024

Jul 19, 2024

SELL
$12.72 - $19.2 $21,102 - $31,852
-1,659 Reduced 28.1%
4,244 $71,000
Q1 2024

Apr 29, 2024

BUY
$13.81 - $19.33 $32,149 - $45,000
2,328 Added 65.12%
5,903 $89,000
Q4 2023

May 21, 2024

SELL
$10.87 - $15.93 $25,305 - $37,085
-2,328 Reduced 39.44%
3,575 $53,000
Q4 2023

Jan 23, 2024

BUY
$10.87 - $15.93 $30,446 - $44,619
2,801 Added 361.89%
3,575 $54,000
Q3 2023

May 21, 2024

BUY
$8.84 - $22.64 $4,128 - $10,572
467 Added 152.12%
774 $10,000
Q3 2023

Oct 30, 2023

BUY
$8.84 - $22.64 $4,128 - $10,572
467 Added 152.12%
774 $11,000
Q2 2023

May 21, 2024

SELL
$8.75 - $14.29 $52 - $85
-6 Reduced 1.92%
307 $3,000
Q2 2023

Jul 27, 2023

SELL
$8.75 - $14.29 $52 - $85
-6 Reduced 1.92%
307 $3,000
Q1 2023

May 21, 2024

BUY
$7.99 - $11.02 $631 - $870
79 Added 33.76%
313 $2,000
Q1 2023

Apr 27, 2023

BUY
$7.99 - $11.02 $631 - $870
79 Added 33.76%
313 $3,000
Q4 2022

May 21, 2024

SELL
$7.55 - $11.96 $42,800 - $67,801
-5,669 Reduced 96.04%
234 $2,000
Q4 2022

Jan 31, 2023

BUY
$7.55 - $11.96 $158 - $251
21 Added 9.86%
234 $2,000
Q3 2022

Oct 21, 2022

BUY
$7.21 - $9.41 $1,535 - $2,004
213 New
213 $2,000

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $242M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.